Michael H. Cho

Michael H. Cho

Auto-generated profile, based on publicly available information

Michael H. Cho

Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2019 in Nature Genetics
Verified
Journal Article
Open access
PDF file
NSNick Shrine
Nick Shrine
AGAnna L. Guyatt
Anna L. Guyatt
AEA Mesut Erzurumluoglu
A Mesut Erzurumluoglu
VJVictoria E. Jackson
Victoria E. Jackson
BHBrian D. Hobbs
Brian D. Hobbs
UGUnderstanding Society Scientific Group
Understanding Society Scientific Group
Reduced lung function predicts mortality and is key to the diagnosis of chronic obstructive pulmonary disease (COPD). In a genome-wide association study in 400,102 individuals of European ancestry, we define 279 lung function signals, 139 of which are new. In combination, these variants strongly predict COPD in independent populations. Furthermore, the combined effect of these variants showed generalizability across smokers and never smokers, and across ancestral groups. We highlight biological pathways, known and potential drug targets for COPD and, in phenome-wide association studies, autoimmune-related and other pleiotropic effects of lung function–associated variants. This new genetic evidence has potential to improve future preventive and therapeutic strategies for COPD.

25 February 2019 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
PSPhuwanat Sakornsakolpat
Phuwanat Sakornsakolpat
DPDmitry Prokopenko
Dmitry Prokopenko
MLMaxime Lamontagne
Maxime Lamontagne
NRNicola F. Reeve
Nicola F. Reeve
AGAnna L. Guyatt
Anna L. Guyatt
MCMichael H. Cho
Michael H. Cho

6 February 2017 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
CICOPDGene Investigators
COPDGene Investigators
BHBrian D Hobbs
Brian D Hobbs
EIECLIPSE Investigators
ECLIPSE Investigators
LILifeLines Investigators
LifeLines Investigators
SGSPIROMICS Research Group
SPIROMICS Research Group
MCMichael H Cho
Michael H Cho

6 August 2014 in Respiratory Research
Verified
Journal Article
Open access
PDF file
EWEmily S Wan
Emily S Wan
PCPeter J Castaldi
Peter J Castaldi
MCMichael H Cho
Michael H Cho
JHJohn E Hokanson
John E Hokanson
ERElizabeth A Regan
Elizabeth A Regan
ESEdwin K Silverman
Edwin K Silverman
Preserved Ratio Impaired Spirometry (PRISm), defined as a reduced FEV1 in the setting of a preserved FEV1/FVC ratio, is highly prevalent and is associated with increased respiratory symptoms, systemic inflammation, and mortality. Studies investigating quantitative chest tomographic features, genetic associations, and subtypes in PRISm subjects have not been reported. Data from current and former smokers enrolled in COPDGene (n = 10,192), an observational, cross-sectional study which recruited subjects aged 45–80 with ≥10 pack years of smoking, were analyzed. To identify epidemiological and radiographic predictors of PRISm, we performed univariate and multivariate analyses comparing PRISm subjects both to control subjects with normal spirometry and to subjects with COPD. To investigate common genetic predictors of PRISm, we performed a genome-wide association study (GWAS). To explore potential subgroups within PRISm, we performed unsupervised k-means clustering. The prevalence of PRISm in COPDGene is 12.3%. Increased dyspnea, reduced 6-minute walk distance, increased percent emphysema and decreased total lung capacity, as well as increased segmental bronchial wall area percentage were significant predictors (p-value <0.05) of PRISm status when compared to control subjects in multivariate models. Although no common genetic variants were identified on GWAS testing, a significant association with Klinefelter’s syndrome (47XXY) was observed (p-value < 0.001). Subgroups identified through k-means clustering include a putative “COPD-subtype”, “Restrictive-subtype”, and a highly symptomatic “Metabolic-subtype”. PRISm subjects are clinically and genetically heterogeneous. Future investigations into the pathophysiological mechanisms behind and potential treatment options for subgroups within PRISm are warranted. Clinicaltrials.gov Identifier: NCT000608764 .

1 March 2014 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
MCMichael H Cho
Michael H Cho
MMMerry-Lynn N McDonald
Merry-Lynn N McDonald
XZXiaobo Zhou
Xiaobo Zhou
MMManuel Mattheisen
Manuel Mattheisen
PCPeter J Castaldi
Peter J Castaldi
TBTerri H Beaty
Terri H Beaty

6 February 2017 in Nature Genetics
Verified
Journal Article
Open access
PDF file
UGUnderstanding Society Scientific Group
Understanding Society Scientific Group
LWLouise V Wain
Louise V Wain
GCGeisinger-Regeneron DiscovEHR Collaboration
Geisinger-Regeneron DiscovEHR Collaboration
NSNick Shrine
Nick Shrine
MAMaría Soler Artigas
María Soler Artigas
MTMartin D Tobin
Martin D Tobin
Louise Wain, Ian Hall, Martin Tobin and colleagues report genome-wide association analyses of lung function, identifying 43 new signals associated with one or more lung function traits. A genetic risk score derived from these results was significantly associated with risk for chronic obstructive pulmonary disease in independent populations. Chronic obstructive pulmonary disease (COPD) is characterized by reduced lung function and is the third leading cause of death globally. Through genome-wide association discovery in 48,943 individuals, selected from extremes of the lung function distribution in UK Biobank, and follow-up in 95,375 individuals, we increased the yield of independent signals for lung function from 54 to 97. A genetic risk score was associated with COPD susceptibility (odds ratio per 1 s.d. of the risk score (∼6 alleles) (95% confidence interval) = 1.24 (1.20–1.27), P = 5.05 × 10−49), and we observed a 3.7-fold difference in COPD risk between individuals in the highest and lowest genetic risk score deciles in UK Biobank. The 97 signals show enrichment in genes for development, elastic fibers and epigenetic regulation pathways. We highlight targets for drugs and compounds in development for COPD and asthma (genes in the inositol phosphate metabolism pathway and CHRM3) and describe targets for potential drug repositioning from other clinical indications.